Teva Pharmaceuticals Industries has appointed Dipanker Bhattacharjee president and CEO of its Global Generic Medicines Group, effective immediately.
“Dipankar has been an integral part of Teva's management team since he joined the Company in 2009, and we are fortunate to have someone with his experience to lead our generics business at this important time,” Teva President and CEO Erez Vigodman said. “Teva will benefit from Dipankar’s extensive experience in generics and specialty medicines.”
Since 2013, Bhattacharjee has held the position of president and CEO of Teva Generics Europe. In his new role with Teva, he will succeed Sigurdur Olafsson, who is stepping down from the role. Bhattacharjee will be based in the U.S.
“As we continue to focus on integrating and realizing the value of the Actavis Generics transaction, which is progressing according to plan, Dipankar and his team will focus on generating organic growth through new launches and replenishing the pipeline through our industry-leading R&D, and drive efficiencies across the generics organization,” Vigodman said. “I have been incredibly impressed by Dipankar’s work in Europe, and I am confident that his capabilities, proven track record and experience make him the right person for this global leadership role.”